DKSH, PacBio, Chulalongkorn University Partner to Launch ‘LIFE-SEQ’, Asia’s First Genomic Program for Precision Health

Bangkok, Thailand - September 15, 2025 - DKSH Business Unit Technology, a leading market expansion services provider, and PacBio, a global leader in high-accuracy genome sequencing, partner with the Center of Excellence for Medical Genomics, Faculty of Medicine, Chulalongkorn University, one of Thailand's most established medical centers to launch the project "LIFE-SEQ (Live-long Initiative for Future Excellence through long-read SEQuencing)". This groundbreaking initiative leverages HiFi genome sequencing technology to advance precision health, offering lifelong care from birth, beginning with newborn screening and rare disease detection in Thailand.

By partnering with PacBio and the Center of Excellence for Medical Genomics and launching the LIFE-SEQ project, DKSH is able to mark a new milestone by bringing HiFi whole-genome sequencing into clinical care in Asia. As the exclusive distributor of PacBio in Thailand, DKSH facilitates access to a PacBio sequencing platform and has provided a team of experts in human genomics. In the initial phase, trained medical specialists will provide free sequencing for 300 newborns at the Chulalongkorn University's Faculty of Medicine in Bangkok. The next phase will expand the program to include more newborns nationwide and follow participants across their lifespan. Ultimately, LIFE-SEQ aims to deliver benefits for people of all ages in Thailand, making cutting-edge genomic healthcare accessible from birth through old age, and advancing precision health for future generations.

HiFi whole genome sequencing helps deliver long, highly accurate DNA reads that provide a complete view of the genome. This enables earlier detection of genetic variants, supporting faster diagnosis, targeted treatment, and ultimately, the potential to save lives. Beyond individual diagnoses, the program's genomic data will be integrated into national research efforts and stored in a structured genomic database to support long-term healthcare planning.

With its Asia-first implementation and nationwide expansion plans, LIFE-SEQ represents a major milestone in Thailand's journey toward precision health. It allows building evidence-based health policies rooted in the Thai genome, its risk factors, and population-specific traits. It also allows to position the market as a regional leader in genomics by strengthening research, digital infrastructure, and clinical applications, laying the foundation for personalized, data-driven healthcare.

"Our shared goal is to determine whether individuals with access to genomic data experience better quality of life compared to those without, and to evaluate the economic impact of such an approach. We perform long-read whole-genome sequencing from the very start of life. The first application is in newborn screening, enabling early identification of genetic causes of otherwise undiagnosed conditions. As participants grow, additional benefits emerge, including carrier testing for family planning, detection of actionable genetic variants relevant to cancer and other noncommunicable diseases, and pharmacogenomic insights to guide treatment across the lifespan," said Prof. Vorasuk Shotelersuk, M.D. Director, Center of Excellence for Medical Genomics, Faculty of Medicine, Chulalongkorn University Thailand.

"Bringing this technology to Thailand is about making a meaningful difference in how we detect and treat genetic conditions. DKSH is proud to have played a hands-on role in enabling this collaboration, which we believe sets a new benchmark for precision healthcare in the region and helps improve the life of Thai people," said Kongsak Ermukdakul, Managing Director, Business Unit Technology, DKSH Thailand.

"Every child deserves the best possible start to life, and that begins with giving families and clinicians access to comprehensive genomic information from the very beginning," said Christian Henry, President and Chief Executive Officer of PacBio. "This collaboration demonstrates how advanced sequencing technologies like HiFi can provide broader insights at birth. It is deeply aligned with PacBio's mission to make high-quality genomic information accessible where it's needed most, and we are proud to support Chulalongkorn University and Thailand as they lead the way in shaping a new model of care."

About Faculty of Medicine, Chulalongkorn University in Thailand Chulalongkorn University is the oldest national university in the Kingdom of Thailand. The university has been active in international research activities and is committed to creating knowledge and innovation to transform Thai society into a creative and sustainable future. As part of the university's mission is to contribute the knowledge gained to the sustainable development of the country and society, the Faculty of Medicine is also actively involved in sharing knowledge with society through collaboration between industry, government, and academia. https://www.md.chula.ac.th About PacBio PacBio (NASDAQ: PACB) is a leading life science technology company that develops advanced sequencing solutions to help researchers resolve genetically complex problems. With HiFi long-read and SBB® short-read technologies, PacBio provides complete and accurate sequencing for applications across human genomics, oncology, infectious disease, agriculture, and more. https://www.pacb.com About DKSH For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Technology offers complete solutions for specialized scientific and industrial applications. With around 1,820 specialists, the Business Unit generated net sales of CHF 549 million in 2024. https://www.dksh.com/tec